Search
Isoflavone
go.drugbank.com/drugs/DB12007ApprovedInvestigationalWithdrawnSoybean is an exceptionally rich source of dietary isoflavones, where the average isoflavone content is 1-2 mg/gram [A33103]. … Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation.
Phenothrin
go.drugbank.com/drugs/DB13717InvestigationalMixtures: HERKLIN CLÁSICO-DUOCategories: Compounds used in a research, industrial, or household settingZucapsaicin
go.drugbank.com/drugs/DB09120ApprovedWithdrawnZucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.
Quercus acutissima whole
go.drugbank.com/drugs/DB14373InvestigationalQuercus acutissima whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Dr. Forest Hand Sanitizer, Dr. Forest Hand SanitizerTragacanth
go.drugbank.com/drugs/DB10667ApprovedTragacanth allergenic extract is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household setting2,2'-Dibenzothiazyl disulfide
go.drugbank.com/drugs/DB14201Approved2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer.
Synonyms: di(1,3-benzothiazol-2-yl) disulfideAbciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnIt also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Anagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigational[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929] … Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.
DA-8031
go.drugbank.com/drugs/DB19024InvestigationalDA-8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation).